CoChat

Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

The HIV integrase (IN) strand transfer inhibitor (INSTI) bictegravir (BIC) has a long dissociation half-life ( t 1/2 ) from wild-type IN-DNA complexes: BIC 163 h > dolutegravir (DTG) 96 h > raltegravir (RAL) 10 h > elvitegravir (EVG) 3.3 h. In cells, BIC had more durable antiviral activity against wild-type HIV after drug washout than RAL or EVG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.02406-20

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG 1 Viral replication of WT (A) and G140S+Q148H (B) variants after treatment with DTG, BIC, EVG, and RAL following drug washout (Δ) starting at washout day 0 (3 days postinfection). Drug levels corresponded to 20 times the 90% inhibitory concentration in this system (38 nM for BIC, 41.7 nM for DTG, 93.75 nM for RAL, and 24 nM for EVG). Replication was assessed by measuring RT activity in culture supernatant without and after drug washout. Bar graphs, mean ± SEM. Statistical significance of drug washout with drug control conditions were assessed by adjusted P value with Tukey’s test: *, <0.05; ***, <0.001; and ****, <0.0001. For the washout experiments, BIC and EVG were synthesized at Gilead Sciences, Inc., DTG was purchased from Toronto Research Chemicals (ON, Canada), and RAL was provided by Merck, Inc.
FIG 1 Viral replication of WT (A) and G140S+Q148H (B) variants after treatment with DTG, BIC, EVG, and RAL following drug washout (Δ) starting at washout day 0 (3 days postinfection). Drug levels corresponded to 20 times the 90% inhibitory concentration in this system (38 nM for BIC, 41.7 nM for DTG, 93.75 nM for RAL, and 24 nM for EVG). Replication was assessed by measuring RT activity in culture supernatant without and after drug washout. Bar graphs, mean ± SEM. Statistical significance of drug washout with drug control conditions were assessed by adjusted P value with Tukey’s test: *, <0.05; ***, <0.001; and ****, <0.0001. For the washout experiments, BIC and EVG were synthesized at Gilead Sciences, Inc., DTG was purchased from Toronto Research Chemicals (ON, Canada), and RAL was provided by Merck, Inc.CC BY · PubMed Central
FIG 2 Molecular models of BIC (A, gray), DTG (B, yellow), and overlap (C) bound to the HIV-1 IN active site. HIV-1 IN and vDNA are shown in blue-red-white and rainbow electrostatic surface representation, respectively. The two Mg2+ ions are shown in magenta spheres. The bicyclic A-ring of BIC makes van der Waals contacts with the IN β4-α2 loop (G118 shown for reference) and 3′-dA of the vDNA, filling up this region of the binding pocket efficiently and acting as additional anchoring points. DTG with its monocyclic ring and flipped stereochemistry makes partial contact with this region. Compound 2 (C, green) is a stereoisomer of BIC (gray) where the bicyclic ring points away from the 3′-dA vDNA. The optimal contacts of BIC with IN β4-α2 loop and vDNA may be major contributors to anchoring the inhibitor in the pocket. Methodologies for the models are as follows. The INSTIs were docked to a homology model of WT and G140S+Q148H mutant HIV-1 IN based on cryo-EM structures (SIVrcm IN) (2) using Prime in Schrodinger Suite 2019-2 (Schrödinger, LLC, New York, NY) and a knowledge-based approach (23). The sequence alignment between SIVrcm IN (template) and HIV-1 IN (query) was optimized using ClustalW (24), yielding a sequence identity of 73%, a sequence similarity of 83%. The residues that were similar between the two sequences were retained while building the model. The side chains of the residues that were not part of the template were iteratively sampled using a coarse library of rotamers derived from known PDB structures until no clashes remained. The coordinates of all atoms not derived directly from the template itself were then minimized, producing the final refined model. BIC, DTG, and compound 2 were prepared with LigPrep with the metal binding states option using Schrodinger Suite 2019 (Schrödinger). INSTIs were docked using Glide XP docking protocol with expanded sampling method (25). Solvent molecules that coordinate to active site Mg2+ ions were kept in place during docking. Top three docked poses for both the INSTIs were saved as an output.
FIG 2 Molecular models of BIC (A, gray), DTG (B, yellow), and overlap (C) bound to the HIV-1 IN active site. HIV-1 IN and vDNA are shown in blue-red-white and rainbow electrostatic surface representation, respectively. The two Mg2+ ions are shown in magenta spheres. The bicyclic A-ring of BIC makes van der Waals contacts with the IN β4-α2 loop (G118 shown for reference) and 3′-dA of the vDNA, filling up this region of the binding pocket efficiently and acting as additional anchoring points. DTG with its monocyclic ring and flipped stereochemistry makes partial contact with this region. Compound 2 (C, green) is a stereoisomer of BIC (gray) where the bicyclic ring points away from the 3′-dA vDNA. The optimal contacts of BIC with IN β4-α2 loop and vDNA may be major contributors to anchoring the inhibitor in the pocket. Methodologies for the models are as follows. The INSTIs were docked to a homology model of WT and G140S+Q148H mutant HIV-1 IN based on cryo-EM structures (SIVrcm IN) (2) using Prime in Schrodinger Suite 2019-2 (Schrödinger, LLC, New York, NY) and a knowledge-based approach (23). The sequence alignment between SIVrcm IN (template) and HIV-1 IN (query) was optimized using ClustalW (24), yielding a sequence identity of 73%, a sequence similarity of 83%. The residues that were similar between the two sequences were retained while building the model. The side chains of the residues that were not part of the template were iteratively sampled using a coarse library of rotamers derived from known PDB structures until no clashes remained. The coordinates of all atoms not derived directly from the template itself were then minimized, producing the final refined model. BIC, DTG, and compound 2 were prepared with LigPrep with the metal binding states option using Schrodinger Suite 2019 (Schrödinger). INSTIs were docked using Glide XP docking protocol with expanded sampling method (25). Solvent molecules that coordinate to active site Mg2+ ions were kept in place during docking. Top three docked poses for both the INSTIs were saved as an output.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Underwood M, Pappa KA, Smith KY, Gartland M, Aboud M, van Wyk J, Wynne B. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection—3-year results from the Gemini studies, poster 018. HIV Glasgow, 5 to 8 October 2020.

Cited by

See all 42

Metadata

Authors
White, K. L., Osman, N., Cuadra-Foy, E., Brenner, B. G., Shivakumar, D., Campigotto, F., Tsiang, M., Morganelli, P. A., Novikov, N., Lazerwith, S. E., Jin, H., & Niedziela-Majka, A.
Affiliations
  • Gilead Sciences (United States) (US)
  • Jewish General Hospital (CA)
  • Gilead Sciences, Inc., Foster City, California, USA
Corresponding author
White, Kirsten L.
Venue
Antimicrobial Agents and Chemotherapy
Published
2021-04-19
Volume
65
Issue
5
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W3134682517
Cited by
33
References
24
Citations by year
2026: 3 · 2025: 9 · 2024: 6 · 2023: 8 · 2022: 4 · 2021: 3
FWCI
1.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
bictegravir, HIV-1 integrase, integrase inhibitors, integrase-DNA complex, drug washout, drug resistance mutations, dolutegravir, drug residence time, antiviral activity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.